In a strategic move to strengthen its position in the high-precision surgical consumables market, Healthium Medtech has acquired Paramount Surgimed’s surgical business, adding surgical blades and dermal biopsy devices to its growing portfolio. The transaction, which excludes Paramount’s non-surgical offerings, brings together two manufacturing powerhouses with complementary capabilities—Paramount’s 250-million-device-per-year capacity and global export footprint across 100+ countries, combined with Healthium’s established presence in 90+ markets and track record of launching 35+ new products in four years.
In an exclusive conversation, Anish Bafna, CEO & MD of Healthium Medtech, shares insights on the strategic rationale behind the acquisition, integration priorities, and how this combination positions India as a rising hub for precision medtech manufacturing on the global stage.
- How does the acquisition of Paramount Surgimed strengthen Healthium’s position in the high-precision surgical consumables segment?
Healthium’s acquisition of Paramount Surgimed builds on its existing leadership in surgical consumables by deepening category strength in high-precision, high-usage segments. The addition of surgical blades and dermal biopsy devices represents a natural extension of Healthium’s portfolio, strengthening its global surgical consumables business while advancing its strategy of delivering high-precision technology to healthcare professionals worldwide.
The integration also expands Healthium’s ability to offer a more comprehensive and integrated set of solutions across the surgical workflow. By combining complementary product lines, the platform broadens customer choice and enhances the overall value proposition, while Paramount’s scaled manufacturing capabilities support Healthium’s ability to meet growing demand with consistency and quality.
Anchored by Healthium’s scale and market reach, the combined platform is positioned to accelerate commercial expansion and enable the development of differentiated, high-quality innovations. Together, these strengths reinforce Healthium’s leadership in high-precision surgical consumables and support its continued growth as a globally competitive medtech player.
- What were the primary strategic considerations behind choosing Paramount Surgimed as an acquisition target?
Healthium has consistently focused on strengthening its surgical consumables platform through deeper category coverage, manufacturing resilience and long-term market readiness and this informed the decision to proceed with Paramount Surgimed as an acquisition partner. Paramount brings over three decades of specialised manufacturing expertise and operates one of the largest platforms in its category, including a large-scale manufacturing facility in Bhiwadi with the capability to produce more than 250 million devices annually. This scale aligns well with Healthium’s own network of 6 high-precision, integrated manufacturing facilities built to global regulatory standards.
Another key consideration was Paramount’s globally oriented business model and established customer relationships. With more than 95% of its revenue generated through exports, Paramount serves over 300 OEM and branded customers across 100+ countries, supported by comprehensive international regulatory registrations including EU MDR and US FDA. These strengths complement Healthium’s certified manufacturing base with approvals such as US FDA, CDSCO, TGA, ISO, cGMP, MDSAP and CE under the new EUDMR norms, as well as its established export presence across more than 90+ countries.
Paramount’s consistent track record of precision, quality and trust further informed the decision. Healthium, which has launched over 35+ new products in the last four years including a patented arthroscopy portfolio, is focused on ensuring a smooth integration that preserves these customer-valued strengths while enhancing service standards and delivery consistency through a larger, scaled platform. Together, the combination enables Healthium to align complementary capabilities toward a more competitive global position in surgical consumables and strengthen access to high-precision technologies across markets.
- What key synergies do you expect to realise in the near term across manufacturing, quality, and commercial operations?
Healthium’s initial priorities are focused on aligning the combined platform in ways that enhance its long-term operating leverage. The emphasis is on strengthening how the portfolio is taken to market and how manufacturing and quality capabilities are scaled in support of that effort.
From a commercial perspective, the combined portfolio creates greater coherence at the account level, allowing Healthium to engage customers with a more integrated proposition. This supports deeper, more durable relationships and positions the organisation to play a more meaningful role across customer purchasing decisions.
On the manufacturing and quality front, the focus is on transferring best practices from Healthium’s scaled, state-of-the-art manufacturing and quality systems in sutures and suture needles. These capabilities provide a strong foundation to further improve manufacturing efficiencies, introduce higher levels of automation and enhance capacity, while continuing to uphold stringent quality and compliance standards.
- How are you planning the integration of Paramount into Healthium to ensure uninterrupted service and continuity for existing customers?
In any combination of operating platforms, preserving continuity for customers is critical to maintaining trust and performance. Consistent with this imperative, Healthium’s integration approach is focused on ensuring uninterrupted service, with existing commercial, manufacturing and functional teams continuing to serve customers while providing access to a broader combined product portfolio. This expanded access allows customers to address a wider range of clinical requirements through existing relationships, improving convenience and breadth of choice without changing how they engage or are supported.
- Why was it important to structure this deal around Paramount’s surgical business while carving out the non-surgical portfolio?
Healthium has always prioritised building a focused portfolio that serves healthcare professionals within the surgical care environment and this principle shaped how the businesses were brought together. Paramount’s surgical business aligns closely with Healthium’s core priorities in surgical consumables, where specialisation and clinical relevance are central to long-term growth.
Paramount’s non-surgical portfolio, which includes adult incontinence and lifestyle products, operates in categories that sit outside Healthium’s strategic focus. Separating these businesses ensures clarity of direction, allowing Healthium to remain concentrated on surgical care while enabling the non-surgical portfolio to continue independently under dedicated ownership.
This approach maintains strategic focus, ensures portfolio coherence and allows leadership attention and resources to remain directed toward areas where Healthium is best positioned to create value.
- In what ways will the combined strengths of Healthium and Paramount shape your future R&D and product innovation roadmap in surgical consumables?
Innovation at Healthium is guided by a disciplined R&D approach that prioritises clinical relevance, manufacturability and long-term portfolio development. The integration with Paramount strengthens this foundation by combining complementary technical capabilities and deep category expertise within surgical consumables.
Access to broader clinical insight and specialised know-how in precision blades and biopsy devices allows R&D teams to focus on product enhancements that address real operating-room requirements. This supports the development of differentiated consumables that improve performance, consistency and usability, while maintaining high standards of safety and quality.
Closer alignment between development and manufacturing enables innovations to move more efficiently from concept to scale. Shared technical platforms support faster refinement, tighter process control and robust production scale-up across high-usage consumable categories.
As a result, Healthium is better positioned to advance its surgical consumables portfolio through targeted, execution-ready innovation that delivers sustained value for clinicians and healthcare systems.
- How will Paramount’s global export footprint and regulatory approvals influence Healthium’s international growth strategy?
Healthium will leverage Paramount’s global export footprint and regulatory approvals to advance its international growth strategy with greater speed, consistency and regulatory assurance. Integrating these capabilities into Healthium’s existing global platform strengthens its ability to expand across markets while maintaining high standards of compliance and execution.
Paramount’s exposure across multiple regulatory regimes supports more efficient market entry and expansion by reducing operational complexity and accelerating product deployment. Access to internationally approved product portfolios enables Healthium to scale its surgical consumables business in a structured manner, supporting faster commercial rollout without compromising regulatory discipline.
The integration also enhances Healthium’s engagement with global OEM and branded partners by strengthening regulatory preparedness and supply reliability. Collectively, these capabilities reinforce Healthium’s position in regulated markets and support sustainable international expansion across its surgical consumables portfolio.
- What impact do you foresee this acquisition having on India’s role as a medtech manufacturing and export hub, particularly in surgical consumables?
India’s medtech manufacturing sector is progressively evolving toward higher-value, precision-led production, particularly within the surgical consumables category. In this context, Healthium’s recent acquisition of Paramount Surgimed contributes to the development of this segment by consolidating specialised manufacturing expertise and technical know-how in precision-engineered consumables, while also unlocking new opportunities across global markets through greater speed and scale.
India’s medical devices market was valued at approximately US$16 billion in 2025 and is expected to grow toward US$30–50 billion by 2030, supported by sustained healthcare demand, targeted manufacturing incentives and regulatory consolidation. As the sector evolves, surgical consumables are assuming increased importance due to their high utilisation, repeat demand and central role across the surgical care continuum.
At an ecosystem level, the development underscores Healthium’s commitment to strengthening India’s medtech manufacturing base, expanding access to globally benchmarked products and supporting innovation-led growth across surgical care. By reinforcing organised capabilities in surgical consumables, Healthium supports deeper integration into global medtech supply chains and contributes to India’s position as a reliable source of high-quality medical devices.
- From a clinician and hospital perspective, what changes or benefits should they expect to see as this partnership progresses?
Healthium has always strived to support the surgical ecosystem through focused, high-quality solutions delivered at scale. As the Healthium-Paramount partnership progresses, hospitals can expect consolidated access to a broader, globally benchmarked portfolio through Healthium, simplifying procurement, standardisation and supply management across surgical departments.
For clinicians, the emphasis remains on consistency at the point of care. They can expect continuity in the quality, performance and regulatory rigour of products offered through Healthium, including devices that meet stringent global standards such as US FDA and EU MDR approvals. This ensures familiarity in product behaviour and confidence in clinical use, even as the portfolio expands.
Thus, we expect the partnership to deliver operational simplicity for hospitals and sustained clinical assurance for surgeons, without altering existing workflows or expectations.
- Following this transaction, what are Healthium’s immediate priorities for growth—both organically and through potential future partnerships or acquisitions?
Healthium’s growth strategy is guided by a clear focus on strengthening its core businesses while selectively expanding the platform where there is strategic alignment. This is evident in the company’s strong organic performance across domestic and export markets, driven by sustainable growth levers embedded across its business lines.
To complement this, Healthium plans to add synergistic assets that strengthen its presence in priority segments such as cardiac, orthopaedics, endoscopy and surgical instruments and consumables, ensuring portfolio expansion remains aligned with its operating model and long-term objectives.
In parallel, Healthium is pursuing partnership-led growth through in-licensing and technical collaborations with companies offering differentiated products or technologies. These collaborations are intended to broaden access to innovation for both Indian and global markets.
This framework allows Healthium to build on organic momentum while expanding selectively and coherently, supporting sustained growth and long-term relevance across markets.
